1 Min Read
April 25 (Reuters) - Obseva Sa
* Obseva initiates phase 3 clinical program for OBE2109 in uterine fibroids Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.